诺和诺德:GLP-1/GIP/Amylin三靶点激动剂启动二期临床

医药笔记
Sep 23

▎Armstrong2025年9月22日,诺和诺德在Clinicaltrials.gov网站上注册了NNC0662-0419用于减重的二期临床试验。该二期临床试验计划入组220例肥胖或超重受试者,预计2026年底完成。根据临床试验注册信息和官网信息,NNC0662-0419应为GLP-1/GIP/Amylin三靶点激动剂,应为NN9662。诺和诺德布局了两款三靶点激动剂,包括自研的GLP-1/...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10